证券代码：605116 证券简称：奥锐特 公告编号：2025-037 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 关于债券持有人持有可转债比例变动达到 10%的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、可转债配售情况 经中国证券监督管理委员会《关于同意奥锐特药业股份有限公司向不特定 对象发行可转换公司债券注册的批复》（证监许可〔2024〕924 号）同意，奥锐 特药业股份有限公司（以下简称"公司"）于 2024 年 7 月 26 日向不特定对象发 行 812.12 万张可转换公司债券，每张面值为人民币 100 元，发行总额 812,120,000.00 元，期限 6 年。经上海证券交易所自律监管决定书[2024]104 号文同意，公司本次发行的可转债于 2024 年 8 月 15 日起在上海证券交易所挂 牌交易，债券简称"奥锐转债"，债券代码"111021"。 公司控股股东浙江桐本投资有限公司（以下简称"桐本投资"）及其一致行 动人天台铂融投资合伙企业（有限合伙）（以下简称"铂融投资"） ...

| 证券代码：605116 | 证券简称：奥锐特 | 公告编号：2025-035 | | --- | --- | --- | | 债券代码：111021 | 债券简称：奥锐转债 | | 奥锐特药业股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/1/22 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 12 个月 | | 预计回购金额 | 6,000万元~12,000万元 | | 回购用途 | □减少注册资本 □用于员工持股计划或股权激励 | | | √用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 136.09万股 | | 累计已回购股数占总股本比例 | 0.34% | | 累计已回购金额 | 27,090,786元 | | 实际回购价格区间 | 18.83元/股~21.00元/股 | 一、回购股份的基本情况 2025 年 1 月 21 日，奥锐 ...

证券代码：605116 证券简称：奥锐特 公告编号：2025-034 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 关于使用部分闲置募集资金进行现金管理进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 现金管理受托方：兴业银行股份有限公司台州临海支行（以下简称"兴 业银行"） 已履行的审议程序：奥锐特药业股份有限公司（以下简称"公司"或"奥 锐特"）于 2024 年 8 月 27 日召开第三届董事会第八次会议及第三届监事会第八 次会议分别审议通过了《关于使用部分闲置募集资金进行现金管理的议案》，同 意公司及子公司使用闲置募集资金不超过人民币 3 亿元进行现金管理，上述额度 可以滚动使用，自第三届董事会第八次会议审议通过之日起 12 个月内有效，并 授权公司管理层在上述额度内行使决策权，具体事项由公司财务部负责组织实施。 具体内容详见公司于 2024 年 8 月 29 日披露于上海证券交易所网站 （www.sse.com.cn）的《奥锐特药业股份有限公司关于使用部分闲置募集资金进 行 ...

证券代码：605116 证券简称：奥锐特 公告编号：2025-033 债券代码：111021 债券简称：奥锐转债 2025 年 4 月 8 日，公司使用部分闲置募集资金人民币 4,500 万元购买了兴 业银行企业金融人民币结构性存款产品，现上述产品已赎回，具体情况如下： 单位：人民币万元 | 序 | 受托方名称 | 产品名称 | 认购金额 | 产品期限 | | | | 赎回情况 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | | | | | | | 本金金额 | 收益金额 | | | | | | 2025 | 年 | 4 | | | | | 兴业银行股份 | 兴业银行企业金 | | | | | | | | | | | | 月 9 | 日 | 至 | | | | 1 | 有限公司台州 | 融人民币结构性 | 4,500 | | | | 4,500 | 5.70 | | | | | | 2025 | 年 | 4 | | | | | 临海支行 | 存款产品 | | | | | | | | | | | | 月 30 | 日 | | | | ...

Core Viewpoint - The company achieved good revenue and profit growth in 2024, with overall performance meeting expectations. The profit level in Q1 2025 showed good growth, slightly exceeding previous expectations. The raw material drug segment maintained steady growth, with strong performance in cardiovascular, respiratory, and anti-infection categories. The formulation business expanded, actively pursuing overseas markets, and the company partnered with East China Normal University to develop AI small nucleic acid drug discovery [1][4][6]. Financial Performance - In 2024, the company reported revenue of 1.476 billion, a year-on-year increase of 16.89%; net profit attributable to shareholders was 355 million, up 22.59%; and net profit excluding non-recurring items was 351 million, up 34.25% [2][4]. - For Q1 2025, the company recorded revenue of 402 million, a year-on-year increase of 19.78%; net profit attributable to shareholders was 119 million, up 45.30%; and net profit excluding non-recurring items was 113 million, up 37.51% [2][4]. Dividend Distribution - The company plans to distribute a cash dividend of 2.90 per 10 shares (including tax), totaling 118 million in cash dividends [3]. Raw Material Drug Segment - The raw material drug intermediate business generated revenue of 1.14 billion in 2024, a year-on-year increase of 7.73%. Key segments included: 1. Cardiovascular drugs with revenue of 432 million, up 43.81% 2. Respiratory drugs with revenue of 191 million, up 16.80% 3. Anti-infection drugs with revenue of 25 million, up 34.49% 4. Female health products with revenue of 126 million, down 33.11% [4][5]. Formulation Business Expansion - The formulation business performed well in 2024, achieving revenue of 220 million, a year-on-year increase of 144.87%. The company improved its distributor network and academic team for promoting Dydrogesterone, expanding its market presence [5]. AI Drug Discovery Collaboration - In March 2025, the company signed an agreement with East China Normal University to establish a joint laboratory for AI small nucleic acid drug discovery, aiming to leverage AI technology for accelerating drug discovery processes [6]. Profitability and Cost Control - The company reported a gross margin of 58.56% and a net margin of 24.04% in 2024, indicating steady improvement in profitability. The sales expense ratio was 8.84%, while the management expense ratio was 11.53%, reflecting good overall cost control [7]. Future Outlook - Key areas to watch include: 1. Expansion of raw material drug capacity, with ongoing projects expected to contribute significantly to revenue in 2025. 2. Continued expansion of the formulation business and overseas market penetration, with multiple new product applications in progress [8]. Earnings Forecast - The company forecasts revenues of 1.791 billion, 2.125 billion, and 2.595 billion for 2025-2027, representing year-on-year growth of 21.4%, 18.6%, and 22.2%, respectively. Net profits are expected to be 463 million, 561 million, and 707 million, with corresponding growth rates of 30.5%, 21.2%, and 26.1% [9].

Investment Rating - The investment rating for the company is "Accumulate" [6] Core Views - The company is expected to achieve rapid growth in revenue and profit in 2024, driven by the robust development of its core API business and the rapid expansion of its formulation business. The company has high competitive barriers, a rich product portfolio, and a unique second growth curve [1][2] Financial Performance - In 2024, the company achieved revenue of 1.476 billion yuan (up 16.89% year-on-year) and a net profit attributable to shareholders of 355 million yuan (up 22.59 year-on-year). The net profit after deducting non-recurring items was 351 million yuan (up 34.25% year-on-year) [2] - For Q1 2025, the company reported revenue of 402 million yuan (up 19.78% year-on-year) and a net profit attributable to shareholders of 119 million yuan (up 45.30% year-on-year) [2] Growth Analysis - The API and intermediate business generated revenue of 1.141 billion yuan in 2024 (up 7.73% year-on-year), with cardiovascular products contributing 432 million yuan (up 43.81% year-on-year). The formulation business achieved revenue of 220 million yuan (up 144.87% year-on-year) due to increased terminal coverage of Dydrogesterone tablets [2][3] Profitability - The company's gross margin for 2024 was 58.56% (up 2.64 percentage points year-on-year), and the net profit margin was 24.04% (up 1.14 percentage points year-on-year). The improvement in profitability is attributed to the higher proportion of high-margin formulation business and improved margins in certain API products [4] Earnings Forecast and Valuation - The expected EPS for 2025, 2026, and 2027 are 1.14 yuan, 1.45 yuan, and 1.77 yuan per share, respectively. The company is projected to maintain steady revenue and profit growth supported by its high-barrier API and formulation products [5]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved a revenue of 1.476 billion yuan in 2024, representing a year-on-year increase of 16.89%. The net profit attributable to the parent company was 355 million yuan, up 22.59% year-on-year. The gross margin was 58.56%, an increase of 2.62 percentage points, and the net margin was 24.04%, up 1.14 percentage points [5] - In Q1 2025, the company reported a revenue of 402 million yuan, a year-on-year increase of 19.78%, and a net profit attributable to the parent company of 119 million yuan, up 45.3% year-on-year. The gross margin improved to 60.73%, an increase of 7.05 percentage points, while the net margin reached 29.71%, up 5.22 percentage points [5] - The company has a high proportion of export revenue, which has led to adjustments in profit forecasts due to significant exchange rate fluctuations. The revised net profit estimates for 2025-2027 are 486 million, 591 million, and 683 million yuan, respectively [5] Financial Performance Summary - In 2024, the cardiovascular raw material drug revenue was 432 million yuan, up 43.81%, with a gross margin of 67.74%. The anti-tumor raw material drug revenue was 212 million yuan, down 13.31%, and the female health raw material drug revenue was 126 million yuan, down 33.11% [6] - The company's formulation business revenue reached 220 million yuan in 2024, a significant increase of 144.87%, with a gross margin of 84.71%. The company has successfully launched a product in 31 provinces and cities [7] Financial Projections and Valuation Metrics - The company is projected to achieve revenues of 1.985 billion yuan in 2025, 2.448 billion yuan in 2026, and 2.802 billion yuan in 2027, with year-on-year growth rates of 34.5%, 23.3%, and 14.5%, respectively [9] - The estimated net profit for 2025 is 486 million yuan, with a projected P/E ratio of 17.8, and for 2026, the net profit is expected to be 591 million yuan with a P/E ratio of 14.6 [9]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved a revenue of 1.476 billion yuan in 2024, representing a year-on-year increase of 16.89%. The net profit attributable to the parent company was 355 million yuan, up 22.59% year-on-year. The gross margin was 58.56%, an increase of 2.62 percentage points, and the net margin was 24.04%, up 1.14 percentage points [5] - In Q1 2025, the company reported a revenue of 402 million yuan, a year-on-year increase of 19.78%, and a net profit attributable to the parent company of 119 million yuan, up 45.3% year-on-year. The gross margin was 60.73%, an increase of 7.05 percentage points, and the net margin was 29.71%, up 5.22 percentage points [5] - The company is expected to benefit from the rapid expansion of its formulation business and the approval of new formulation varieties in the coming years, with the API of Semaglutide expected to contribute to performance growth [5] Financial Summary - The company’s total revenue is projected to grow from 1.263 billion yuan in 2023 to 2.802 billion yuan in 2027, with a compound annual growth rate (CAGR) of 25.2% [9] - The net profit attributable to the parent company is expected to increase from 289 million yuan in 2023 to 683 million yuan in 2027, reflecting a CAGR of 37.2% [9] - The gross margin is forecasted to improve from 55.9% in 2023 to 64.3% in 2027, while the net margin is expected to remain stable around 24% [9][12] - The company’s P/E ratio is projected to decrease from 29.9 in 2023 to 12.7 in 2027, indicating an attractive valuation as earnings grow [9]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The report highlights significant achievements in the company's integrated transformation, particularly in the growth of peptide and oligonucleotide segments [7] - The company reported a revenue of 1.476 billion yuan in 2024, representing a year-on-year increase of 16.89%, and a net profit attributable to shareholders of 354.79 million yuan, up 22.59% [7] - The report anticipates continued growth in the raw material drug sector, with a focus on the expansion of peptide and oligonucleotide products as new growth drivers [7] Financial Summary - Total revenue projections for the company are as follows: 1.263 billion yuan in 2023, 1.476 billion yuan in 2024, 1.842 billion yuan in 2025, 2.158 billion yuan in 2026, and 2.750 billion yuan in 2027, with respective year-on-year growth rates of 25.24%, 16.89%, 24.79%, 17.19%, and 27.42% [1][8] - The net profit attributable to shareholders is projected to be 289.42 million yuan in 2023, 354.79 million yuan in 2024, 477.42 million yuan in 2025, 597.50 million yuan in 2026, and 731.69 million yuan in 2027, with year-on-year growth rates of 37.19%, 22.59%, 34.56%, 25.15%, and 22.46% [1][8] - The report provides a P/E ratio forecast of 29.89 for 2023, 24.39 for 2024, 18.12 for 2025, 14.48 for 2026, and 11.82 for 2027 [1][8]

登录新浪财经APP 搜索【信披】查看更多考评等级 公司代码：605116 公司简称：奥锐特 债券代码：111021 债券简称：奥锐转债 第一节 重要提示 1、本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 资者应当到www.sse.com.cn网站仔细阅读年度报告全文。 2、本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、完整 性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 3、公司全体董事出席董事会会议。 4、天健会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 5、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司2024年度利润分配预案为：公司拟向全体股东（不含公司回购专户库存股）每10股派发现金红利 2.90元（含税）。公司不送红股，不进行资本公积转增，剩余未分配利润全部结转以后年度分配。本次 派发现金红利总额将以实施权益分派股权登记日实际有权参与股数为准计算。截至2024年12月31日,公 司总股本406,195,000股，库存股0股，若以此为基数计算，拟派发现金红利总额为 ...